TY  - JOUR
AU  - Teibo, John Oluwafemi
AU  - Silveira, Roberta Maraninchi
AU  - Silvestrini, Virginia Campos
AU  - Archiolli, Izadora
AU  - PaulaMasson, Ana
AU  - de Morais, Beatriz Pereira
AU  - Schmidt, Dayane
AU  - Dos Santos, Matheus Henrique
AU  - Ferreira, Germano Aguiar
AU  - Thomé, Carolina Hassibe
AU  - Helm, Dominic
AU  - Nirujogi, Raja Sekhar
AU  - Alessi, Dairo Renato
AU  - Picanço-Castro, Virginia
AU  - de Souza, Lucas Eduardo Botelho
AU  - Faça, Vitor Marcel
TI  - Proteomics analysis reveals early event molecular effectors of anti-CD19 CAR-T cell therapy in hematological cancer.
JO  - Journal of proteomics
VL  - 321
SN  - 1874-3919
CY  - New York, NY [u.a.]
PB  - Elsevier
M1  - DKFZ-2025-01562
SP  - 105507
PY  - 2025
N1  - Volume 321, 30 October 2025, 105507Journal of Proteomics
AB  - Chimeric antigen receptor T-cell (CAR-T) therapy is at the forefront of the field of cell immunotherapy. In this study, we generated an anti-CD19 CAR-Jurkat T cell line using a locally produced second-generation anti-CD19 CAR construct, which allowed us to analyse early proteomic changes that are crucial for comprehending the signalling pathways and mechanism of action of this CAR-T cell. SILAC-heavy tagged RAJI B-cells and anti-CD19 CAR-Jurkat T-cells were co-cultured for ten minutes. The proteomic profiles were acquired via DIA methodology on the Orbitrap Astral LC-MS/MS platform. The proteome was extensively covered, resulting in about 8800 protein identifications at 1 
KW  - CAR-T cell (Other)
KW  - Early Signalling event (Other)
KW  - Hematological Cancer (Other)
KW  - Molecular effectors (Other)
KW  - Proteomics (Other)
KW  - SILAC (Other)
LB  - PUB:(DE-HGF)16
C6  - pmid:40716489
DO  - DOI:10.1016/j.jprot.2025.105507
UR  - https://inrepo02.dkfz.de/record/303211
ER  -